253 related articles for article (PubMed ID: 34738847)
1. Higher Expression of
Chen C; Chen Z; Chio CL; Zhao Y; Li Y; Liu Z; Jin Z; Wu X; Wei W; Zhao Q; Li Y
Technol Cancer Res Treat; 2021; 20():15330338211052152. PubMed ID: 34738847
[No Abstract] [Full Text] [Related]
2. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.
Damm F; Heuser M; Morgan M; Yun H; Grosshennig A; Göhring G; Schlegelberger B; Döhner K; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Döhner H; Heil G; Ganser A; Krauter J
J Clin Oncol; 2010 Feb; 28(4):578-85. PubMed ID: 20038731
[TBL] [Abstract][Full Text] [Related]
3. Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study.
Hidaka D; Onozawa M; Hashiguchi J; Miyashita N; Kasahara K; Fujisawa S; Hayase E; Okada K; Shiratori S; Goto H; Sugita J; Nakagawa M; Hashimoto D; Kahata K; Endo T; Yamamoto S; Tsutsumi Y; Haseyama Y; Nagashima T; Mori A; Ota S; Sakai H; Ishihara T; Imai K; Miyagishima T; Kakinoki Y; Kurosawa M; Kobayashi H; Iwasaki H; Shimizu C; Kondo T; Teshima T
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e469-e479. PubMed ID: 30082223
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia.
Lyu X; Xin Y; Mi R; Ding J; Wang X; Hu J; Fan R; Wei X; Song Y; Zhao RY
PLoS One; 2014; 9(3):e92470. PubMed ID: 24667279
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and Prognostic Impact of Wilms' Tumor 1 (WT1) Gene, Including SNP rs16754 in Cytogenetically Normal Acute Myeloblastic Leukemia (CN-AML): An Iranian Experience.
Toogeh G; Ramzi M; Faranoush M; Amirizadeh N; Haghpanah S; Moghadam M; Cohan N
Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):e21-6. PubMed ID: 26725263
[TBL] [Abstract][Full Text] [Related]
6. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
Paschka P; Marcucci G; Ruppert AS; Whitman SP; Mrózek K; Maharry K; Langer C; Baldus CD; Zhao W; Powell BL; Baer MR; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
J Clin Oncol; 2008 Oct; 26(28):4595-602. PubMed ID: 18559874
[TBL] [Abstract][Full Text] [Related]
7. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
[TBL] [Abstract][Full Text] [Related]
8. A novel 5-gene prognostic signature to improve risk stratification of cytogenetically normal acute myeloid leukemia.
Deng C; Zeng T; Zhu P; Zhao S; Huang Z; Huang W; Zhang W; Huang X; Fu L
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10015-10025. PubMed ID: 37258721
[TBL] [Abstract][Full Text] [Related]
9. Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients.
Marjanovic I; Karan-Djurasevic T; Ugrin M; Virijevic M; Vidovic A; Tomin D; Suvajdzic Vukovic N; Pavlovic S; Tosic N
Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):312-319. PubMed ID: 28163010
[TBL] [Abstract][Full Text] [Related]
10. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
Becker H; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Margeson D; Whitman SP; Wu YZ; Schwind S; Paschka P; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
J Clin Oncol; 2010 Feb; 28(4):596-604. PubMed ID: 20026798
[TBL] [Abstract][Full Text] [Related]
11. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
12. The Prognostic Significance of PDE7B in Cytogenetically Normal Acute Myeloid Leukemia.
Cao L; Zhang W; Liu X; Yang P; Wang J; Hu K; Zhang X; Liu W; He X; Jing H; Yuan X
Sci Rep; 2019 Nov; 9(1):16991. PubMed ID: 31740742
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia.
Hollink IH; van den Heuvel-Eibrink MM; Zimmermann M; Balgobind BV; Arentsen-Peters ST; Alders M; Willasch A; Kaspers GJ; Trka J; Baruchel A; de Graaf SS; Creutzig U; Pieters R; Reinhardt D; Zwaan CM
Blood; 2009 Jun; 113(23):5951-60. PubMed ID: 19171881
[TBL] [Abstract][Full Text] [Related]
14. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.
Shi JL; Fu L; Wang WD
Oncotarget; 2015 Mar; 6(7):5299-309. PubMed ID: 25779662
[TBL] [Abstract][Full Text] [Related]
15. High expression of CD56 may be associated with favorable overall survival in intermediate-risk acute myeloid leukemia.
Chen C; Chio CL; Zeng H; Li Y
Hematology; 2021 Dec; 26(1):210-214. PubMed ID: 33594945
[TBL] [Abstract][Full Text] [Related]
16. Serial measurement of WT1 expression and decrement ratio until hematopoietic cell transplantation as a marker of residual disease in patients with cytogenetically normal acute myelogenous leukemia.
Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH
Biol Blood Marrow Transplant; 2013 Jun; 19(6):958-66. PubMed ID: 23542687
[TBL] [Abstract][Full Text] [Related]
17. High WT1 expression predicted induction chemotherapy failure in acute myeloid leukemia patients with non-favorable cytogenetic risk.
Xu N; Chen WM; Li LD; Long LY; Wang X; Jiang Q; Jiang H; Huang XJ; Qin YZ
Clin Exp Med; 2023 Oct; 23(6):2629-2638. PubMed ID: 36637581
[TBL] [Abstract][Full Text] [Related]
18. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.
Gaidzik VI; Schlenk RF; Moschny S; Becker A; Bullinger L; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Döhner H; Döhner K;
Blood; 2009 May; 113(19):4505-11. PubMed ID: 19221039
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of PRDM16 expression in acute myeloid leukemia with normal cytogenetics.
Xiang X; Lu Q; Xu X; Cai P; Chen S; Pan J; Zeng Z
Hematology; 2022 Dec; 27(1):499-505. PubMed ID: 35473465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
